Bristol-Myers partner Innate concedes a PhII flop for I/O drug lirilumab in fighting AML
More than five years ago Bristol-Myers Squibb heralded a $465 million deal to partner with Innate Pharma on its natural killer cell cancer drug lirilumab. But today the French biotech was forced to concede that its lead drug was no better than a placebo in fighting acute myeloid leukemia as a monotherapy.
Carrying out plans to handle development through Phase II, Marseilles-based Innate execs said that lirilumab flunked a Phase II trial testing the drug as a single agent. There was no evidence that the drug was any better than placebo in spurring a leukemia-free outcome for patients in a maintenance setting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.